

SUPPLEMENTARY TABLE. Second dose completion status* for two-dose COVID-19 vaccine series among adolescents aged 12–17 years by age — 49 U.S. states† and District of Columbia, December 14, 2020–July 31, 2021

Completion Status	No (%) [§]											
	Overall				Pfizer-BioNTech				Moderna			
	Total	12–13 years	14–15 years	16–17 years	Total	12–13 years	14–15 years	16–17 years	Total	12–13 years	14–15 years	16–17 years
Completed series [¶]	7,808,627 (86.8)	2,195,486 (88.1)	2,500,552 (87.7)	3,112,589 (85.3)	7,737,136 (87.0)	2,193,636 (88.2)	2,497,734 (87.8)	3,045,766 (85.6)	71,491 (72.7)	1,850 (65.9)	2,818 (66.2)	66,823 (73.2)
No second dose but within allowable interval ^{**}	211,562 (2.4)	65,803 (2.6)	70,725 (2.5)	75,034 (2.1)	208,782 (2.3)	65,710 (2.6)	70,641 (2.5)	72,431 (2.0)	2,780 (2.8)	93 (3.3)	84 (2.0)	2,603 (2.9)
Missed second dose ^{††}	971,378 (10.8)	229,582 (9.2)	278,550 (9.8)	463,246 (12.7)	947,275 (10.7)	228,716 (9.2)	277,195 (9.7)	441,364 (12.4)	24,103 (24.5)	866 (30.8)	1,355 (31.8)	21,882 (24.0)

* Among persons who received their first dose on or before July 6, 2021 for Pfizer-BioNTech (i.e., >25 days between the first dose and July 31, 2021) or June 29, 2021 for Moderna (i.e., >32 days between the first dose and July 31, 2021). As of August 17, 2021, only the Pfizer-BioNTech vaccine has been authorized for use among adolescents aged 12–17 years. Moderna COVID-19 vaccines were not authorized under emergency use for this age group from December 14, 2020–July 31, 2021. However, these vaccine doses were included in this analysis.

† COVID-19 vaccine doses administered to adolescents residing in Idaho were excluded as they have data sharing restrictions on information reported to CDC.

§ Because of rounding, column percentages might not sum to 100%.

¶ This includes persons who received the same vaccine type for both doses, as well as those who received mismatched products for the first and second dose (e.g., Pfizer-BioNTech for first dose and Moderna for the second dose, or vice versa).

** “Allowable Interval” is defined as being within 26–42 days from the first dose for Pfizer-BioNTech and being within 33–42 days from the first dose for Moderna.

†† Defined as not having received the second dose >42 days after receiving the first dose.